Discover Veru Inc.'s Q2 2025 earnings highlights, including enobosarm's promising Phase 2b results in weight management, funding plans, and ...

Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be presented at ECO 2025 - covering burden, and the value of treatment and prevention ...

LLY's post-market drop offers investment potential with robust R&D, capex strategies, and strong cash flow, positioning it ...

A decision is expected in the fourth quarter of 2025.

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

The apparent success — and now almost ever-present ubiquity — of GLP-1 receptor agonists in weight loss has led to research, and possible uses, far beyond its initial indications in diabetes, ...

Khalid bin Abdulaziz Al-Falih and several officials, along with representatives from Novo Nordisk and Lifera. Semaglutide GLP-1 treatments are the global market-leading therapeutics for weight ...

Novo Nordisk has become aware of several hundred units of Ozempic® (semaglutide) injection 1 mg distributed outside the Novo Nordisk authorized supply chain in the US. The US Food and Drug ...